These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1337 related articles for article (PubMed ID: 25857211)

  • 41. Developments of specialized pro-resolving mediators in periodontitis.
    Liu YC
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Feb; 39(1):94-98. PubMed ID: 33723943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins.
    Serhan CN
    Curr Opin Clin Nutr Metab Care; 2005 Mar; 8(2):115-21. PubMed ID: 15716788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The biosynthetic pathways of the protectins.
    Stenvik Haatveit Å; Hansen TV
    Prostaglandins Other Lipid Mediat; 2023 Dec; 169():106787. PubMed ID: 37806439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome.
    Kwon Y
    Mol Nutr Food Res; 2020 Feb; 64(4):e1900824. PubMed ID: 31797565
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protectins: Their biosynthesis, metabolism and structure-functions.
    Vidar Hansen T; Serhan CN
    Biochem Pharmacol; 2022 Dec; 206():115330. PubMed ID: 36341938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereoselective syntheses and biological activities of E-series resolvins.
    Vik A; Hansen TV
    Org Biomol Chem; 2021 Jan; 19(4):705-721. PubMed ID: 33410452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases.
    Yacoubian S; Serhan CN
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):570-9; quiz 1 p following 589. PubMed ID: 17906612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation.
    Norris PC; Skulas-Ray AC; Riley I; Richter CK; Kris-Etherton PM; Jensen GL; Serhan CN; Maddipati KR
    Sci Rep; 2018 Dec; 8(1):18050. PubMed ID: 30575798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proresolution mediators and receptors: novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation.
    Grover V; Malhotra R; Kapoor A; Singh J; Sachdeva S
    Infect Disord Drug Targets; 2013 Feb; 13(1):75-84. PubMed ID: 23713671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.
    Serhan CN
    J Periodontol; 2008 Aug; 79(8 Suppl):1520-6. PubMed ID: 18673006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vagus nerve controls resolution and pro-resolving mediators of inflammation.
    Mirakaj V; Dalli J; Granja T; Rosenberger P; Serhan CN
    J Exp Med; 2014 Jun; 211(6):1037-48. PubMed ID: 24863066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition.
    Al-Shaer AE; Buddenbaum N; Shaikh SR
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Jul; 1866(7):158936. PubMed ID: 33794384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease.
    Spite M
    Proc Nutr Soc; 2013 Nov; 72(4):441-50. PubMed ID: 23991833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications.
    Wu B; Mottola G; Schaller M; Upchurch GR; Conte MS
    Mol Aspects Med; 2017 Dec; 58():72-82. PubMed ID: 28765077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The novel lipid mediator PD1
    Hansen TV; Dalli J; Serhan CN
    Prostaglandins Other Lipid Mediat; 2017 Nov; 133():103-110. PubMed ID: 28602942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel anti-inflammatory--pro-resolving mediators and their receptors.
    Serhan CN; Krishnamoorthy S; Recchiuti A; Chiang N
    Curr Top Med Chem; 2011; 11(6):629-47. PubMed ID: 21261595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation.
    Farooqui AA
    Curr Med Chem; 2012; 19(4):532-43. PubMed ID: 22204329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resolvins and protectins in the termination program of acute inflammation.
    Ariel A; Serhan CN
    Trends Immunol; 2007 Apr; 28(4):176-83. PubMed ID: 17337246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [What the surgeon needs to know about basic new concepts of inflammation and their therapeutic consequences: sanitation of inflammation is not a passive but rather an active process regulated by lipid mediators].
    Gardemann A; Meyer F; Braun-Dullaeus R
    Zentralbl Chir; 2013 Jun; 138(3):322-30. PubMed ID: 23807584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases.
    Tang S; Wan M; Huang W; Stanton RC; Xu Y
    Mediators Inflamm; 2018; 2018():2380319. PubMed ID: 29674943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.